专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011111027A2 ORAL DISPERSIBLE DELAYED RELEASE TABLET FORMULATION 审中-公开
标题翻译：口服不适当的延迟释放片剂制剂
公开(公告)号：WO2011111027A2
公开(公告)日：2011-09-15
申请号：PCT/IB2011/051031
申请日：2011-03-11
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel , GOMBERG, Maxim , MEISLER, Tal , GAUCHMAN, Janina
发明人： PENHASI, Adel , GOMBERG, Maxim , MEISLER, Tal , GAUCHMAN, Janina
CPC分类号： A61K9/2072 , A61K9/2009 , A61K9/2018 , A61K9/2846 , A61K9/2886
摘要： A formulation for delivery of a therapeutic agent to the small intestine which features a combination of a single delayed release mini-tablet for delivery to the gastrointestinal tract, surrounded by a fast disintegrating tablet layer which dissolves in the oral cavity. The oral disintegrating tablet which undergoes rapid disintegration in the oral cavity supports ease of swallowing and hence ease of administration of the mini-tablet, which is responsible for delayed release of a therapeutic agent in the small intestine. The mini-tablet preferably has a relatively small diameter, smaller than that of a regular tablet.
摘要翻译：用于将治疗剂递送到小肠的制剂，其特征在于用于递送至胃肠道的单一延迟释放微型片剂的组合，其被溶解在口腔中的快速崩解片剂层包围。在口腔中快速崩解的口腔崩解片剂容易吞咽，因此易于施用微小片剂，微小片剂导致小肠中治疗剂的延迟释放。迷你片优选具有相对小的直径，小于普通片剂的直径。

2. 发明申请

WO2006103661A2 CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE 审中-公开
标题翻译：控制在INTESTINE中吸收统计数据
公开(公告)号：WO2006103661A2
公开(公告)日：2006-10-05
申请号：PCT/IL2006/000387
申请日：2006-03-27
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel , RUDERMAN, Marina , GOMBERG, Maxim
发明人： PENHASI, Adel , RUDERMAN, Marina , GOMBERG, Maxim
IPC分类号： A61K9/56
CPC分类号： A61K31/00 , A61K9/2846 , A61K9/2866
摘要： A delayed onset controlled release formulation is provided in which controlled release of the active ingredient occurs preferentially in the lower gastrointestinal tract including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, over which an outer coating is layered. The core is optionally and preferably in the form of a tablet.
摘要翻译：提供延迟发作控制释放制剂，其中活性成分的控制释放优先在包括结肠的下胃肠道中。该制剂支持比目前使用的常规制剂可以实现的受试者体内活性成分显着更高的生物利用度，使得他汀在给药后长时间内维持治疗上显着的血浆水平。制剂优选具有芯，其上层叠有外涂层。芯可选地优选为片剂的形式。

3. 发明申请

WO2008044236A3 IMPROVED RELEASE OF STATINS IN THE INTESTINE 审中-公开
公开(公告)号：WO2008044236A3
公开(公告)日：2008-04-17
申请号：PCT/IL2007/001220
申请日：2007-10-09
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel , GOMBERG, Maxim
发明人： PENHASI, Adel , GOMBERG, Maxim
IPC分类号： A61K9/20
摘要： The present invention provides a controlled absorption formulation in which modified release of the active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than that can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation features a core, a subcoat surrounding the core comprising at least one water soluble hydrophilic carrier and an outer coating. The core is optionally and preferably in the form of a tablet.

4. 发明申请

WO2005115380A2 LOCALIZED CONTROLLED ABSORPTION OF STATINS IN THE GASTROINTESTINAL TRACT FOR ACHIEVING HIGH BLOOD LEVELS OF STATINS 审中-公开
标题翻译：局部控制吸收统计学处理高血压水平的胃肠道疾病
公开(公告)号：WO2005115380A2
公开(公告)日：2005-12-08
申请号：PCT/IL2005/000539
申请日：2005-05-26
申请人： DEXCEL PHARMA TECHNOLOGIES LTD , PENHASI, Adel , GOMBERG, Maxim
发明人： PENHASI, Adel , GOMBERG, Maxim
IPC分类号： A61K31/401
CPC分类号： A61K31/366 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/22 , A61K31/401
摘要： The present invention relates to a localized controlled absorption formulation of a statin in which rapid release of the active ingredient preferentially occurs in the lower 5 gastrointestinal tract including the colon. The formulation provides significantly higher blood level concentration and bioavailability of the active ingredient in the body of a subject as compared to the bioavailability achieved from the currently available conventional formulations The blood levels are maintained for a significantly longer period of time as compared with currently available conventional formulations. The formulation preferably 10 includes a core, over which an outer coating is layered. The core preferably includes a burst controlling agent and optionally a disintegrant. The outer coating includes a water insoluble polymer and at least one water permeable agent allowing entry of water into said core, the water permeable agent comprising hydrophilic particulate matter. The core is preferably in the form of a tablet.
摘要翻译：本发明涉及他汀类药物的局部控制吸收制剂，其中活性成分的快速释放优先发生在包括结肠的下部胃肠道5中。与目前可获得的常规制剂相比，该制剂提供了与受试者体内活性成分相比显着更高的血液浓度和生物利用度。与目前可获得的常规制剂相比，血液水平维持较长的时间配方。制剂优选10包括芯，外涂层层叠在芯上。核心优选包括爆发控制剂和任选的崩解剂。外涂层包括水不溶性聚合物和允许水进入所述核心的至少一种水可渗透剂，所述水可渗透剂包含亲水性颗粒物质。核心优选为片剂的形式。

5. 发明申请

WO2009098697A1 MODAFINIL AND SILDENAFIL DOSAGE FORMS 审中-公开
标题翻译： MODAFINIL和SILDENAFIL剂型
公开(公告)号：WO2009098697A1
公开(公告)日：2009-08-13
申请号：PCT/IL2009/000146
申请日：2009-02-08
申请人： Dexxon Ltd. , PENHASI, Adel , GAUCHMAN, Janina , SHAULI, Amanda , RUDERMAN, Marina , AVRAMOFF, Avi
发明人： PENHASI, Adel , GAUCHMAN, Janina , SHAULI, Amanda , RUDERMAN, Marina , AVRAMOFF, Avi
IPC分类号： A61K9/32 , A61K9/48 , A61K31/165 , A61K31/519
CPC分类号： A61K9/2866 , A61K9/284 , A61K9/4808 , A61K31/165 , A61K31/519
摘要： Modified release formulations comprising at least one of modafinil and sildenafil, and combinations thereof, and a time-controlled delivery system coating.
摘要翻译：包含莫达非尼和西地那非或其组合中的至少一种的调释释放制剂和时间控制的递送系统涂层。

6. 发明申请

WO2011001425A1 LOCAL THERAPEUTIC RELEASE DEVICE 审中-公开
标题翻译：局部治疗装置
公开(公告)号：WO2011001425A1
公开(公告)日：2011-01-06
申请号：PCT/IL2010/000509
申请日：2010-06-24
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel , REUVENI, Albert , SHOSHANI, Eyal
发明人： PENHASI, Adel , REUVENI, Albert , SHOSHANI, Eyal
IPC分类号： A61K9/00 , A61K9/16 , A61K9/70 , A61K31/192
CPC分类号： A61K9/0063 , A61K9/1635 , A61K9/1652 , A61K9/1658 , A61K9/7007 , A61K31/192
摘要： An oral delivery device for the treatment of periodontal disease, the device being in a solid unit dosage form configured for insertion into a periodontal pocket of a patient. The device consists of: (a) a biodegradable pharmaceutically acceptable water-insoluble polymer in the form of a matrix; (b) a therapeutically effective amount of at least one anti-inflammatory agent dispersed within the matrix; (c) optionally a plasticizing agent; (d) optionally at least one of a wetting agent, a suspending agent and a dispersing agent; and (e) optionally an enzymatically biodegradable pharmaceutically acceptable water soluble polymer dispersed within the matrix. The biodegradable water-insoluble polymer is degradable by enzymatic degradation, physical disintegration or a combination thereof. Also disclosed is a periodontal implant comprising the device and a method for the treatment of periodontal disease comprising administering to a periodontal pocket of a patient in need of such treatment the delivery device.
摘要翻译：一种用于治疗牙周病的口服递送装置，该装置是被配置成插入到患者的牙周袋中的固体单位剂型。该装置包括：（a）基质形式的可生物降解的可药用的不溶于水的聚合物; （b）分散在基质内的治疗有效量的至少一种抗炎剂; （c）任选的增塑剂; （d）任选的润湿剂，悬浮剂和分散剂中的至少一种; 和（e）任选地分散在基质内的可酶促生物降解的药学上可接受的水溶性聚合物。可生物降解的水不溶性聚合物可通过酶降解，物理崩解或其组合降解。还公开了一种牙周植入物，其包含该装置和用于治疗牙周疾病的方法，包括向需要这种治疗的患者的牙周袋施用递送装置。

7. 发明申请

WO2006054307A3 CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE 审中-公开
公开(公告)号：WO2006054307A3
公开(公告)日：2006-05-26
申请号：PCT/IL2005/001234
申请日：2005-11-22
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel
发明人： PENHASI, Adel
IPC分类号： A61K9/24
摘要： The present invention provides a controlled absorption formulation in which modified release of the active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than that can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, over which an outer coating is layered. The core is optionally and preferably in the form of a tablet.

8. 发明申请

WO2009113061A1 HUMIDITY-RESISTANT DRUG FORMULATIONS AND METHODS OF PREPARATION THEREOF 审中-公开
标题翻译：抗湿性药物制剂及其制备方法
公开(公告)号：WO2009113061A1
公开(公告)日：2009-09-17
申请号：PCT/IL2009/000267
申请日：2009-03-10
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel , ATTALI, Yaakov Stephane
发明人： PENHASI, Adel , ATTALI, Yaakov Stephane
IPC分类号： A61K9/28 , A61K31/40
CPC分类号： A61K9/2886 , A61K9/5073 , A61K31/40
摘要： The present invention provides humidity-resistant and/or environmental factor resistant (such as oxidation resistant) pharmaceutical compositions, comprising: a core comprising an active ingredient or pharmaceutically acceptable salt thereof; a cationic polymer containing coating over the core; and an additional coating over the cationic polymer containing coating, the additional coating comprising an acidifying agent or other agent capable of facilitating the dissolution of the cationic polymer coating; methods of preparing same; and therapeutic methods utilizing same.
摘要翻译：本发明提供耐湿性和/或环境因素抗性（例如耐氧化）药物组合物，其包含：包含活性成分或其药学上可接受的盐的核心; 在芯上包含涂层的阳离子聚合物; 以及在包含阳离子聚合物的涂层上的另外的涂层，所述附加涂层包含酸化剂或能够促进阳离子聚合物涂层溶解的其它试剂; 制备方法; 和使用其的治疗方法。

9. 发明申请

WO2004084873A1 ORAL DELIVERY SYSTEM COMPRISING AN ANTIBACTERIAL AND AN ANTI-INFLAMMATORY AGENT 审中-公开
标题翻译：包含抗真菌剂和抗炎剂的口服递送系统
公开(公告)号：WO2004084873A1
公开(公告)日：2004-10-07
申请号：PCT/IL2004/000252
申请日：2004-03-17
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel , REUVENI, Albert , OREN, Dan
发明人： PENHASI, Adel , REUVENI, Albert , OREN, Dan
IPC分类号： A61K9/70
CPC分类号： A61K9/0024 , A61K9/0063 , A61K9/7007 , A61K31/155 , A61K31/19 , A61K45/06 , A61K2300/00
摘要： The present invention provides an oral delivery system for the treatment of periodontal disease, being in a solid unit dosage form for administration to a patient and comprising: (i) a biodegradable or bioerodible pharmaceutically acceptable polymer; (ii) a therapeutically effective amount of at least one antibacterial agent; and (iii) a therapeutically effective amount of at least one anti-inflammatory agent, the relative weight ratio between the antibacterial agent and the anti-inflammatory agent ranking from about 7:1 to about 1:5. The system may further comprise at least one of a cross-linking agent, a plasticizing agent, a wetting agent, a suspending agent, a surfactant and a dispersing agent.
摘要翻译：本发明提供了一种用于治疗牙周病的口服递送系统，其为用于给予患者的固体单位剂型，其包含：（i）可生物降解或可生物侵蚀的药学上可接受的聚合物; （ii）治疗有效量的至少一种抗菌剂; 和（iii）治疗有效量的至少一种抗炎剂，抗菌剂和抗炎剂之间的相对重量比为约7:1至约1:5。该系统还可以包含交联剂，增塑剂，润湿剂，悬浮剂，表面活性剂和分散剂中的至少一种。

10. 发明申请

WO2006054308A2 STABLE ATORVASTATIN FORMULATIONS 审中-公开
标题翻译：稳定的ATORVASTATIN制剂
公开(公告)号：WO2006054308A2
公开(公告)日：2006-05-26
申请号：PCT/IL2005/001235
申请日：2005-11-22
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel , ATTALI, Yaakov Stephane
发明人： PENHASI, Adel , ATTALI, Yaakov Stephane
IPC分类号： A61K31/401 , A61K9/14
CPC分类号： A61K31/401 , A61K9/2018 , A61K9/2059
摘要： A simple yet efficient formulation for providing excellent bioefficacy, wherein the formulation comprises atorvastatin or a salt thereof, optionally in a crystalline or amorphous form, wherein at least one pharmaceutical excipient is selected according to a form of atorvastatin, for example for greater stability. Preferably the formulation lacks a stabilizer.
摘要翻译：一种用于提供优异生物功效的简单而有效的制剂，其中所述制剂包含阿托伐他汀或其盐，任选呈结晶或无定形形式，其中根据阿托伐他汀的形式选择至少一种药物赋形剂，例如用于更大的稳定性。优选地，制剂缺乏稳定剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式